Xianghu Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xianghu Meng has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Rijin Song
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
5 shared publications Yibo Hua
Department of Urology, The First Afffliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, 210029, PR China
4 shared publicationsRong Cong
Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing 210029, Jiangsu, Peoples R China
2 shared publicationsChi Gan
Department of Urology The First Affiliated Hospital of Nanjing Medical University Nanjing P. R. China
1 shared publicationGuiting Lin
Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA 94134, USA
1 shared publicationHaijun Gu
Day Surgery Center, First Affiliated Hospital with Nanjing Medical University, 210029 Nanjing, Jiangsu, China
1 shared publication
Latest Publications
- Open Access
- 31 July 2026
- Published by Wolters Kluwer Health in Asian Journal of Andrology
- Vol. 28 (6) , 728-735
Erectile dysfunction in aging men: evidence and insights related to antihypertensive and antidiabetic medications
With global population aging, erectile dysfunction is becoming increasingly prevalent among middle-aged and older men, who frequently present with cardiometabolic comorbidities, such as hypertension and diabetes mellitus. Although these conditions are well-established risk factors for erectile dysfunction, their long-term pharmacological management may exert heterogeneous and adverse effects on erectile function, complicating clinical decision-making. This review synthesizes current evidence on the shared pathophysiological mechanisms linking erectile dysfunction with hypertension and diabetes mellitus, including endothelial dysfunction, oxidative stress, vascular remodeling, metabolic dysregulation, and neurovascular impairment. This review also critically evaluates the effects of commonly prescribed antihypertensive and antidiabetic drug classes on erectile function, highlighting both their beneficial and detrimental profiles. By integrating mechanistic insights with clinical evidence, this review highlights medication-associated sexual dysfunction in aging men. It emphasizes its recognition and management in clinical practice. The goal is to guide individualized treatment strategies that control cardiometabolic disease while preserving sexual health and quality of life.
- 31 July 2026
- Published by Wolters Kluwer Health in Asian Journal of Andrology
- Vol. 28 (6) , 728-735
Open AccessErectile dysfunction in aging men: evidence and insights related to antihypertensive and antidiabetic medications
With global population aging, erectile dysfunction is becoming increasingly prevalent among middle-aged and older men, who frequently present with cardiometabolic comorbidities, such as hypertension and diabetes mellitus. Although these conditions are well-established risk factors for erectile dysfunction, their long-term pharmacological management may exert heterogeneous and adverse effects on erectile function, complicating clinical decision-making. This review synthesizes current evidence on the shared pathophysiological mechanisms linking erectile dysfunction with hypertension and diabetes mellitus, including endothelial dysfunction, oxidative stress, vascular remodeling, metabolic dysregulation, and neurovascular impairment. This review also critically evaluates the effects of commonly prescribed antihypertensive and antidiabetic drug classes on erectile function, highlighting both their beneficial and detrimental profiles. By integrating mechanistic insights with clinical evidence, this review highlights medication-associated sexual dysfunction in aging men. It emphasizes its recognition and management in clinical practice. The goal is to guide individualized treatment strategies that control cardiometabolic disease while preserving sexual health and quality of life.
- Open Access
- 14 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (36) , e24169
Design of Single‐Atom Nanozymes for Precision Treatment of Erectile Dysfunction with Integrated Single‐Cell RNA Sequencing and Machine Learning
Patients with diabetes mellitus‐induced erectile dysfunction (DMED) usually suffer more severe symptoms, and efficacy of the first‐line therapy is limited. This study develops an integrated framework combining single‐cell RNA sequencing (scRNA‐seq) and machine learning (ML) to design nanozymes with specific enzyme‐mimicking types for precision treatment of DMED. First, scRNA‐seq analysis demonstrated increased reactive oxygen species (ROS) level and downregulated expression level of glutathione peroxidase (GPx), catalase (CAT) and superoxide dismutase (SOD) in the corpus cavernosum of DMED patients. Second, a nanozyme database is constructed based on the published researches. With this database, two ML models are developed to predict the enzyme‐mimicking types of nanozymes, which showed that iron (Fe)‐based nanozymes are particularly suitable for addressing reductase deficiencies in DMED. Thus, the Fe‐DMOF, an Fe‐based single atom nanozyme (SAzyme), is synthesized, simultaneously exhibiting GPx‐, CAT‐ and SOD‐like activities. Fe‐DMOF can significantly reduce the ROS accumulation and inhibit the ROS‐induced histone lactylation modifications, furtherly reversing the inflammatory differentiation of fibroblasts and macrophages in the diabetic corpus cavernosum. These results not only highlight the efficacy of Fe‐DMOF in DMED treatment, but also validate the scRNA‐seq + ML framework as an effective approach for data‐driven SAzyme design for disease‐specific treatment.
- 14 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (36) , e24169
Open AccessDesign of Single‐Atom Nanozymes for Precision Treatment of Erectile Dysfunction with Integrated Single‐Cell RNA Sequencing and Machine Learning
Patients with diabetes mellitus‐induced erectile dysfunction (DMED) usually suffer more severe symptoms, and efficacy of the first‐line therapy is limited. This study develops an integrated framework combining single‐cell RNA sequencing (scRNA‐seq) and machine learning (ML) to design nanozymes with specific enzyme‐mimicking types for precision treatment of DMED. First, scRNA‐seq analysis demonstrated increased reactive oxygen species (ROS) level and downregulated expression level of glutathione peroxidase (GPx), catalase (CAT) and superoxide dismutase (SOD) in the corpus cavernosum of DMED patients. Second, a nanozyme database is constructed based on the published researches. With this database, two ML models are developed to predict the enzyme‐mimicking types of nanozymes, which showed that iron (Fe)‐based nanozymes are particularly suitable for addressing reductase deficiencies in DMED. Thus, the Fe‐DMOF, an Fe‐based single atom nanozyme (SAzyme), is synthesized, simultaneously exhibiting GPx‐, CAT‐ and SOD‐like activities. Fe‐DMOF can significantly reduce the ROS accumulation and inhibit the ROS‐induced histone lactylation modifications, furtherly reversing the inflammatory differentiation of fibroblasts and macrophages in the diabetic corpus cavernosum. These results not only highlight the efficacy of Fe‐DMOF in DMED treatment, but also validate the scRNA‐seq + ML framework as an effective approach for data‐driven SAzyme design for disease‐specific treatment.
- Open Access
- 1 July 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 43, 102116
Genetic architecture and mechanisms shared between kidney and ureteral stones, cardiovascular diseases, and metabolic syndrome: A comprehensive GWAS analysis
- 1 July 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 43, 102116
Open AccessGenetic architecture and mechanisms shared between kidney and ureteral stones, cardiovascular diseases, and metabolic syndrome: A comprehensive GWAS analysis
- Open Access
- 1 January 2025
- Published by Archivos Espanoles de Urologia in Archivos Espanoles de Urologia
- Vol. 78 (8) , 1064-1071
Efficacy and Safety of Same-Day Flexible Ureteroscopic Lithotripsy: Comparative Study of Navigable Suction versus Conventional Ureteral Access Sheaths
Purpose: This study aimed to assess the efficacy and safety of same-da...
- 1 January 2025
- Published by Archivos Espanoles de Urologia in Archivos Espanoles de Urologia
- Vol. 78 (8) , 1064-1071
Open AccessEfficacy and Safety of Same-Day Flexible Ureteroscopic Lithotripsy: Comparative Study of Navigable Suction versus Conventional Ureteral Access Sheaths
Purpose: This study aimed to assess the efficacy and safety of same-da...
- 26 November 2024
- Published by Springer Nature in Urolithiasis
- Vol. 52 (1) , 1-16
Exploring the molecular interactions between nephrolithiasis and carotid atherosclerosis: asporin as a potential biomarker
Increasing evidence suggested nephrolithiasis has a close linkage with carotid atherosclerosis (CAS), with Randall’s plaque (RP) being a precursor to kidney stones. Our study aimed to examine the crosstalk genes and potential molecular mechanisms between RP and CAS. We obtained microarray data for RP and CAS from the Gene Expression Omnibus (GEO) and used weighted gene co-expression network analysis (WGCNA) and differential gene expression (DEG) analysis to identify shared genes. By integrating WGCNA and DEG analysis, Asporin (ASPN) was identified as the key gene connecting RP and CAS, with its diagnostic potential assessed via a receiver operating characteristic (ROC) curve. Immune infiltration studies showed a significant correlation between ASPN and various immune cells in RP and CAS. ASPN was found to be less expressed in RP and CAS tissues compared to normal tissues, as confirmed by immunohistochemistry (IHC) and quantitative reverse-transcription PCR (qRT-PCR). The rat model confirmed the human tissue findings. ASPN can elucidate the shared pathogenic mechanisms underlying the two conditions, including immune response and osteoblast differentiation.
- 26 November 2024
- Published by Springer Nature in Urolithiasis
- Vol. 52 (1) , 1-16
Exploring the molecular interactions between nephrolithiasis and carotid atherosclerosis: asporin as a potential biomarker
Increasing evidence suggested nephrolithiasis has a close linkage with carotid atherosclerosis (CAS), with Randall’s plaque (RP) being a precursor to kidney stones. Our study aimed to examine the crosstalk genes and potential molecular mechanisms between RP and CAS. We obtained microarray data for RP and CAS from the Gene Expression Omnibus (GEO) and used weighted gene co-expression network analysis (WGCNA) and differential gene expression (DEG) analysis to identify shared genes. By integrating WGCNA and DEG analysis, Asporin (ASPN) was identified as the key gene connecting RP and CAS, with its diagnostic potential assessed via a receiver operating characteristic (ROC) curve. Immune infiltration studies showed a significant correlation between ASPN and various immune cells in RP and CAS. ASPN was found to be less expressed in RP and CAS tissues compared to normal tissues, as confirmed by immunohistochemistry (IHC) and quantitative reverse-transcription PCR (qRT-PCR). The rat model confirmed the human tissue findings. ASPN can elucidate the shared pathogenic mechanisms underlying the two conditions, including immune response and osteoblast differentiation.
- Open Access
- 1 January 2024
- Published by Archivos Espanoles de Urologia in Archivos Espanoles de Urologia
- Vol. 77 (4) , 446-450
Analysis of Hemorrhagic Shock Following Percutaneous Nephrolithotomy Resulting from Diaphragm Injury: A Case Report
Background: Percutaneous nephrolithotomy (PCNL) is the first treatment...
- 1 January 2024
- Published by Archivos Espanoles de Urologia in Archivos Espanoles de Urologia
- Vol. 77 (4) , 446-450
Open AccessAnalysis of Hemorrhagic Shock Following Percutaneous Nephrolithotomy Resulting from Diaphragm Injury: A Case Report
Background: Percutaneous nephrolithotomy (PCNL) is the first treatment...
- Open Access
- 1 April 2020
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 9 (2) , 344-354
Integrative analysis of ceRNA network and DNA methylation associated with gene expression in malignant pheochromocytomas: a study based on The Cancer Genome Atlas
Background: Competitive endogenous RNAs (ceRNAs) have revealed a new mechanism of interaction between RNAs. Epigenetic regulation in the gene expression dynamics has become increasingly important in malignant pheochromocytomas (PCCs). We performed an integrative analysis of ceRNA networks and DNA methylation to identify key biomarkers and contribute to the understanding of the molecular biological mechanisms of malignant PCCs. Methods: Differentially expressed genes in malignant PCCs and controls were identified from The Cancer Genome Atlas database by using the Limma package in R (v3.4.4). An abnormal lncRNA-miRNA-mRNA ceRNA network was constructed for malignant PCCs, and function enrichment analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery. For DNA methylation datasets, the methylation analysis package was used in identifying differential methylation genes, and potential prognostic genes were identified by Kaplan-Meier survival analysis. Results: A total of 447 lncRNAs, 26 miRNAs, and 1,607 mRNAs were found to be differentially expressed in malignant PCCs as compared with those in normal samples. We then constructed an abnormal lncRNA-miRNA-mRNA ceRNA network for malignant PCCs. The network consisted of 12 lncRNAs, 6 miRNAs, and 220 mRNAs. Functional enrichment analysis showed that differentially expressed mRNAs were particularly enriched in the biological process, cellular component, and molecular function. Furthermore, four differentially expressed mRNAs from ceRNAs were identified through the cross-analysis of gene expression and DNA methylation profiles. LncRNA C9orf147 and 6 out of 220 mRNAs were indicated as prognostic biomarkers for patients with malignant PCCs (PConclusions: Our research increases the understanding of the pathogenesis of malignant PCCs and offers potential genes as underlying therapeutic targets or prognostic biomarkers.
- 1 April 2020
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 9 (2) , 344-354
Open AccessIntegrative analysis of ceRNA network and DNA methylation associated with gene expression in malignant pheochromocytomas: a study based on The Cancer Genome Atlas
Background: Competitive endogenous RNAs (ceRNAs) have revealed a new mechanism of interaction between RNAs. Epigenetic regulation in the gene expression dynamics has become increasingly important in malignant pheochromocytomas (PCCs). We performed an integrative analysis of ceRNA networks and DNA methylation to identify key biomarkers and contribute to the understanding of the molecular biological mechanisms of malignant PCCs. Methods: Differentially expressed genes in malignant PCCs and controls were identified from The Cancer Genome Atlas database by using the Limma package in R (v3.4.4). An abnormal lncRNA-miRNA-mRNA ceRNA network was constructed for malignant PCCs, and function enrichment analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery. For DNA methylation datasets, the methylation analysis package was used in identifying differential methylation genes, and potential prognostic genes were identified by Kaplan-Meier survival analysis. Results: A total of 447 lncRNAs, 26 miRNAs, and 1,607 mRNAs were found to be differentially expressed in malignant PCCs as compared with those in normal samples. We then constructed an abnormal lncRNA-miRNA-mRNA ceRNA network for malignant PCCs. The network consisted of 12 lncRNAs, 6 miRNAs, and 220 mRNAs. Functional enrichment analysis showed that differentially expressed mRNAs were particularly enriched in the biological process, cellular component, and molecular function. Furthermore, four differentially expressed mRNAs from ceRNAs were identified through the cross-analysis of gene expression and DNA methylation profiles. LncRNA C9orf147 and 6 out of 220 mRNAs were indicated as prognostic biomarkers for patients with malignant PCCs (PConclusions: Our research increases the understanding of the pathogenesis of malignant PCCs and offers potential genes as underlying therapeutic targets or prognostic biomarkers.